LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.28 4.92

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.16

Max

1.29

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
EPS	-0.43
Gewinnspanne	-2,190.837
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+147.93% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.5M 94M
Vorheriger Eröffnungskurs	-3.64
Vorheriger Schlusskurs	1.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Dez. 2025, 23:48 UTC

Wichtige Markttreiber

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8. Dez. 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8. Dez. 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8. Dez. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Dez. 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8. Dez. 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8. Dez. 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8. Dez. 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8. Dez. 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Dez. 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8. Dez. 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8. Dez. 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8. Dez. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8. Dez. 2025, 21:12 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. Dez. 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8. Dez. 2025, 20:38 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8. Dez. 2025, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. Dez. 2025, 20:18 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8. Dez. 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8. Dez. 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8. Dez. 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Dez. 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8. Dez. 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

147.93% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 147.93%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.